Table 3. The changes of symptom scores and VUDS parameters after the first and repeat external urethral sphincter onabotulinumtoxinA injection therapy within dysfunctional voiding (DV) and detrusor underactivity (DU) patients.
| DV (N = 7) |
DU (N = 12) |
|||||
|---|---|---|---|---|---|---|
| Changes after the 1st injection | Changes after repeat injection | P value# | Changes after the 1st Injection | Changes after repeat injection | P value# | |
| IPSS-V | −4.0 ± 5.5 | −3.4 ± 5.4 | 0.848 | −1.0 ± 4.0 | −6.3 ± 7.0* | 0.035 |
| IPSS-S | −2.3 ± 3.9 | −3.4 ± 3.3* | 0.563 | −2.1 ± 3.8 | −4.5 ± 5.7* | 0.250 |
| IPSS-T | −6.3 ± 6.7* | −6.9 ± 3.5* | 0.846 | −3.0 ± 5.0 | −10.7 ± 10.8* | 0.051 |
| QoL-I | −1.0 ± 2.2 | −2.0 ± 1.5* | 0.337 | −1.8 ± 1.8* | −3.1 ± 2.2* | 0.144 |
| PPBC | −0.9 ± 2.7 | −1.7 ± 1.8* | 0.502 | −0.9 ± 1.6 | −1.8 ± 1.7* | 0.202 |
| CBC (mL) | 60.6 ± 105.5 | 143.3 ± 143.0* | 0.242 | 32.1 ± 72.8 | 77.2 ± 148.5 | 0.381 |
| Pdet (cmH2O) | −8.1 ± 14.7 | −13.4 ± 21.1 | 0.597 | 5.2 ± 10.7 | 3.8 ± 10.0 | 0.719 |
| Qmax (mL/s) | 1.3 ± 5.2 | 2.6 ± 6.0 | 0.676 | −0.6 ± 3.8 | 5.4 ± 5.5* | 0.008 |
| Vol. (mL) | 17.9 ± 64.7 | 29.7 ± 55.8 | 0.720 | −10.3 ± 94.5 | 57.5 ± 150.5 | 0.206 |
| PVR (mL) | 29.1 ± 104.2 | 21.3 ± 124.7 | 0.900 | −1.3 ± 174.4 | −70.9 ± 179.3 | 0.367 |
| VE (%) | −7.7 ± 25.8 | −1.9 ± 31.8 | 0.715 | −0.2 ± 17.2 | 19.5 ± 37.1 | 0.113 |
#p value between the changes of the parameters after the 1st and repeat injections.
*p value <0.05 versus baseline (or before the injection therapy).
IPSS, International Prostate Symptom Score; IPSS-V, IPSS voiding subscore; IPSS-S: IPSS storage subscore; IPSS-T, total IPSS score; PPBC, Patient Perception of Bladder Condition score; QoL-I, quality of life index; CBC, cystometric bladder capacity; Pdet, detrusor voiding pressure; Qmax, maximal urinary flow rate; Vol., voided volume; PVR, post-void residual; VE, voiding efficiency.
Data are expressed as mean ± standard deviation.